不同立体定向放疗方案对脑转移瘤局部控制与毒性的影响
该回顾性研究分析了2001至2011年间3家学术医院接受立体定向放疗的156例实体脑转移瘤患者,评估不同剂量方案对局部控制、急性毒性和放射性坏死的影响。中位总剂量25 Gy,中位分次剂量5 Gy,中位分次数5次。3、6、12、18、24个月局部进展累积发生率分别为11%、22%、29%、34%、36%。总处方剂量是唯一与局部进展时间显著相关的因素。
要点
- 总处方剂量是唯一与局部控制显著相关的因素。
- 急性和长期毒性事件均较轻微。
- 发生放射性坏死的患者均曾接受过该病灶的放疗。
核心结论
- 总处方剂量是唯一与脑转移瘤立体定向放疗后局部进展时间显著相关的因素。
研究设计与样本
- 回顾性研究,纳入2001至2011年间3家学术医院接受立体定向放疗的156例实体脑转移瘤患者,采用可变剂量方案。
主要发现
- 3、6、12、18、24个月局部进展累积发生率分别为11%、22%、29%、34%、36%。
- 总处方剂量在单因素分析(P = .02)和多因素分析(P = .01,校正风险比0.87)中均与局部进展时间显著相关。
- 5例患者在立体定向放疗后10天内出现癫痫发作,5例发生放射性坏死。
- 所有发生放射性坏死的患者均曾接受过该病灶的放疗。
关键数值与推荐
- 中位靶体积3.99 mL(范围0.04-58.42)。
- 中位总剂量25 Gy(范围12-36),中位分次剂量5 Gy(范围2.5-11),中位分次数5次(范围2-10)。
临床怎么用
- 在制定脑转移瘤立体定向放疗方案时,应重视总处方剂量对局部控制的影响。
- 尽管急性和长期毒性较轻微,对曾接受过放疗的病灶仍需警惕放射性坏死风险。
局限性
- 回顾性研究设计。
- 样本量有限(156例)。
- 剂量方案异质性大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiation therapy (SRT) enables focused, short course, high dose per fraction radiation delivery to brain tumors that are less ideal for single fraction treatment because of size, shape, or close proximity to sensitive structures. We sought to identify optimal SRT treatment regimens for maximizing local control while minimizing morbidity. METHODS AND MATERIALS: We performed a retrospective review of patients treated with SRT for solid brain metastases using variable dose schedules between 2001 and 2011 at 3 academic hospitals. Endpoints included (1) local control, (2) acute toxicity (Common Toxicity Criteria for Adverse Events v3.0), and (3) symptomatic radionecrosis. Kaplan-Meier and a competing risks methodology were used to estimate the actuarial rate of local failure and assess the association of clinical and treatment covariates with time to local failure. RESULTS: A total of 156 patients was identified. Common tumor histologies included breast (21%), non-small cell lung (32%), melanoma (22%), small cell lung (9%), and renal cell carcinoma (6%). The majority of lesions were supratentorial (57%). Median target volume was 3.99 mL (range, 0.04-58.42). Median total SRT dose was 25 Gy (range, 12-36), median fractional dose was 5 Gy (range, 2.5-11), and median number of fractions was 5 (range, 2-10). Cumulative incidence of local progression at 3, 6, 12, 18, and 24 months was 11%, 22%, 29%, 34%, and 36%. Total prescription dose was the only factor significantly associated with time to local progression on univariate (P = .02) and multivariable analysis (P = .01, adjusted hazards ratio, 0.87). Five patients experienced seizures within 10 days of SRT and 5 patients developed radionecrosis. All patients with documented radionecrosis received prior radiation to the index lesion. CONCLUSIONS: Our series of SRT for brain metastases found total prescription dose to be the only factor associated with local control. Both acute and long-term toxicity events from SRT were modest.
引用
- Jimenez RB, Alexander BM, Mahadevan A, et al. The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity. Adv Radiat Oncol. 2017. PMID: 29114607. doi:10.1016/j.adro.2017.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。